Healthcare / BiotechnologyShanghai
$32.45
-1.74 (-5.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $68.2M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
30.6x
↑EV/EBITDA
22.1x
↑ROE
5.2%
↑Gross Margin
89.9%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
+38.6%
FCF margin
6.8%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $915.1M · net income $166.0M · FCF $62.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $915.1M | $915.1M | $825.4M | $920.0M | $866.7M |
| Net Income | $166.0M | $166.0M | $42.2M | $150.5M | $101.5M |
| EBITDA | $233.5M | $233.5M | $81.5M | $168.5M | $179.9M |
| EPS | 1.04 | 1.04 | 0.27 | 0.96 | 0.65 |
| Gross Margin | 89.9% | 89.9% | 89.6% | 89.0% | 85.4% |
| Operating Margin | 21.7% | 21.7% | 15.5% | 15.9% | 15.8% |
| Net Margin | 18.1% | 18.1% | 5.1% | 16.4% | 11.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.07 | 0.05 | 0.00 |
| Current Ratio | 3.05 | 3.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $62.2M | $62.2M | $68.2M | $98.4M | $23.4M |
| Returns | |||||
| ROE | 5.2% | 5.2% | 1.3% | 4.9% | 3.5% |
| Valuation | |||||
| P/E | 30.61 | 30.61 | 82.85 | 38.16 | 39.37 |
| EV/EBITDA | 22.13 | 22.13 | 43.17 | 33.60 | 20.36 |
| P/B | 1.61 | 1.61 | 1.11 | 1.88 | 1.37 |
| Growth & Yield | |||||
| Revenue Growth | 10.9% | 10.9% | -10.3% | 6.1% | — |
| EPS Growth | 285.2% | 285.2% | -71.9% | 47.7% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
40.4%
EPS terminal req.
$2.88
Spread vs growth
244.8%
5Y implied EPS CAGR
27.4%
EPS terminal req.
$3.48
Spread vs growth
257.8%
10Y implied EPS CAGR
18.4%
EPS terminal req.
$5.61
Spread vs growth
266.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.9%
Start / end P/E
111.1x → 31.2x
EPS bridge
0.27 → 1.04
Residual
-205.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.